SPORE in Lymphoma

淋巴瘤中的孢子

• 批准号: 8321631
• 负责人: STEVEN H BERNSTEIN
• 金额: $ 229.93万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8321631
• 关键词: Arizona; B-Cell NonHodgkins Lymphoma; B-Lymphocytes; Biological Models; Biology; Cancer Center; Cells; Clinical; Clinical Trials; Correlative Study; Development; Diffuse; In Vitro; Lead; Lymphoma; Mantle Cell Lymphoma; Non-Hodgkin' s Lymphoma; Oxidation-Reduction; Pathologic; Proteasome Inhibitor; Research Personnel; Research Project Grants; Resistance; Resources; Southwest Oncology Group; Therapeutic; Therapeutic Agents; Time; Translational Research; Universities; aurora kinase; base; design; novel; programs

This Lymphoma SPORE application from the James P. Wilmot Cancer Center (JPWCC), University of Rochester, and the Arizona Cancer Center (ACC), University of Arizona provides a broad based, translational research program studying several major unresolved issues in the lymphoma biology. Specifically the projects will focus on several novel, targeted therapeutic agents either in development or approved for the treatment of three of the most common non-Hodgkin's lymphomas, namely diffuse large B-cell, follicular and mantle cell lymphoma. We will initially seek to elucidate mechanisms of action and/or resistance both in vitro, and in carefully developed model systems; then pilot clinical trials with an emphasis on correlative studies will be designed and conducted to validate these mechanisms. Investigators at the JPWCC and the ACC, long-time collaborators, lead each of the programs. The clinical and pathologic resources of the Lymphoma Committee of the Southwest Oncology Group are also integrated into this program. Projects include: Research Project 1: Targeting Aurora Kinase in Aggressive B-cell non-Hodgkin's Lymphoma, Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL. Project 3: Potentiating Proteasome Inhibitor Activity in NHL. Project 4: Characterization of Lymphoma-lnitiating Cells.

罗切斯特大学（James P. Wilmot）癌症中心（JPWCC）和亚利桑那州癌症中心（ACC）的淋巴瘤孢子应用，亚利桑那大学提供了一项基于广泛的转化研究计划，研究了淋巴瘤生物学中的几个主要未解决的问题。具体而言，这些项目将集中在开发或批准的几种新型的，有针对性的治疗剂上，以治疗三种最常见的非霍奇金淋巴瘤，即弥漫大型B细胞，卵泡和地幔细胞淋巴瘤。我们最初将寻求在体外和精心开发的模型系统中阐明作用和/或抗性机制。然后，将设计和进行强调相关研究的试验临床试验，以验证这些机制。 JPWCC和ACC的调查人员，长期合作者主持了每个计划。西南肿瘤学组淋巴瘤委员会的临床和病理资源也已纳入该计划。项目包括： 研究项目1：靶向激进的B细胞非霍奇金淋巴瘤中的极光激酶， 项目2：将氧化还原调制作为NHL的治疗策略。 项目3：增强NHL中蛋白酶体的抑制剂活性。 项目4：淋巴瘤 - 元素细胞的表征。

项目成果

Update on aurora kinase inhibitors in gynecologic malignancies.

• DOI: 10.2174/157489208786242322
• 发表时间: 2008-11
• 期刊: Recent patents on anti-cancer drug discovery
• 影响因子: 2.8
• 作者: Tao X;Chon HS;Fu S;Kavanagh JJ;Hu W
• 通讯作者: Hu W

Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma.

• DOI: 10.1309/ajcp2z0tagmuyjeb
• 发表时间: 2013-02
• 期刊: American journal of clinical pathology
• 影响因子: 3.5
• 作者: Valentino C;Kendrick S;Johnson N;Gascoyne R;Chan WC;Weisenburger D;Braziel R;Cook JR;Tubbs R;Campo E;Rosenwald A;Ott G;Delabie J;Jaffe E;Zhang W;Brunhoeber P;Nitta H;Grogan T;Rimsza L
• 通讯作者: Rimsza L

Demonstration of array-based analysis for highly multiplexed PCR assays application to detection of IGH@-BCL2 translocations in FFPE follicular lymphoma specimens.

演示基于阵列的高度多重 PCR 检测分析应用于检测 FFPE 滤泡性淋巴瘤标本中的 IGH@-BCL2 易位。

• DOI: 10.1016/j.jmoldx.2010.11.019
• 发表时间: 2011
• 期刊: The Journal of molecular diagnostics : JMD
• 作者: Spence,JaniceM;Rothberg,PaulG;Wang,Nancy;Burack,WRichard
• 通讯作者: Burack,WRichard

Liquefaction and Rupture of Angiomyolipoma after Embolization.

• DOI: 10.1016/j.jvir.2020.05.021
• 发表时间: 2020-12
• 期刊: Journal of vascular and interventional radiology : JVIR
• 作者: Uzzo RN;Drevik J;Panaro J;Geynisman DM
• 通讯作者: Geynisman DM

The emerging role of bendamustine in follicular lymphoma.

苯达莫司汀在滤泡性淋巴瘤中的新作用。

• DOI: 10.1080/10428190902741497
• 发表时间: 2009
• 期刊: Leukemia & lymphoma
• 影响因子: 2.6
• 作者: Friedberg,JonathanW